Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail  

作　　者：Jyoti Bajpai Surya Kant Ajay Kumar Verma Akshyaya Pradhan 

机构地区：[1]Department ofRespiratory Medicine,King George’s Medical University,Lucknow 226003,India [2]Department ofCardiology,King George’s Medical University,Lucknow 226003,India

出　　处：《World Journal of Respirology》2023年第1期1-9,共9页世界呼吸病学杂志

摘　　要：The coronavirus disease 2019(COVID-19)pandemic has had a tremendous adverse impact on the global health system,public sector,and social aspects.It is unarguably the worst pandemic of the century.However,COVID-19 management is a mystery in front of us,and an authentic treatment is urgently needed.Various repurposed drugs,like ivermectin,remdesivir,tocilizumab,baricitinib,etc.,have been used to treat COVID-19,but none are promising.Antibody therapy and their combinations are emerging modalities for treating moderate COVID-19,and they have shown the potential to reduce hospitalisations.One antibody monotherapy,bamlanivimab,and two cocktails,casirivimab/imdevimab and bamlanivimab/esterivimab,have received authorization for emergency use by the United States Food and Drug Administration for the treatment of mild COVID-19 in high risk individuals.The European Emergency has made similar recommendations for use of the drug in COVID-19 patients without oxygen therapy.This brief review will focus on monoclonal antibodies and their combination cocktail therapy in managing COVID-19 infection.

关 键 词：SARS-CoV-2 Mild COVID-19 ANTIBODIES Risk factors 

分 类 号：R73[医药卫生—肿瘤]